3-(2-benzyloxyphenyl)-2-furancarboxylic acid hydrazide | 576169-50-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 3-(2-benzyloxyphenyl)-2-furancarboxylic acid hydrazide
• 英文别名: 3-(2-Phenylmethoxyphenyl)furan-2-carbohydrazide
• CAS: 576169-50-1
• 化学式: C₁₈H₁₆N₂O₃
• 分子量: 308.337
• InChiKey: FSESANLNULYSCI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  77.5
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(2-benzyloxyphenyl)-2-furancarboxylic acid hydrazide 、 3-氰基-4-羟基苯甲酸 在 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 3-(2-benzyloxyphenyl)-2-furancarboxylic acid 2-(3-cyano-4-hydroxybenzoyl)hydrazide
  参考文献：
  名称：

  EP1489077

  摘要：

  公开号：

文献信息

• 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same
  申请人：Fujii Akihito

  公开号：US20050171196A1

  公开（公告）日：2005-08-04

  The present invention provides 2-furancarboxylic acid hydrazide compounds represented by General Formula (I) below, and prodrugs, physiologically acceptable salts, hydrates, solvates thereof, methods for producing them and pharmaceutical compositions containing them: wherein A is a group represented by Formula (a) or the like: (wherein either R 4 or R 5 represents cyano, nitro or the like, and the other represents a hydrogen atom or the like); either R 1 or R 2 represents a group: -D-(X)m-R 6 or the like, and the other represents a group: -E-(Y)n-R 7 , hydrogen atom, aryl or the like; R 3 is a hydrogen atom or the like; D and E independently represent aryl; X and Y independently represent O or the like; R 6 and R 7 independently represent alkyl, aryl, arylalkyl or the like; and m and n are independently 0 or 1, provided that the aryl is optionally substituted. Such compounds exhibit a potent antagonistic activity on glucagon receptor and are of use as preventive and/or therapeutic agents for symptoms and diseases in which glucagon is involved.

  本发明提供了由下列通式（I）表示的2-呋喃羧酸肼化合物，以及它们的前药、生理上可接受的盐、水合物、溶剂化物、制备方法和含有它们的制药组合物：其中A是由式（a）或类似式表示的基团：（其中R4或R5代表氰基、硝基或类似物，另一个代表氢原子或类似物）；R1或R2代表基团：-D-(X)m-R6或类似物，另一个代表基团：-E-(Y)n-R7、氢原子、芳基或类似物；R3是氢原子或类似物；D和E独立地表示芳基；X和Y独立地表示O或类似物；R6和R7独立地表示烷基、芳基、芳基烷基或类似物；m和n独立地表示0或1，但芳基可选择性地被取代。这些化合物表现出强大的胰高血糖素受体拮抗活性，并且可用作预防和/或治疗胰高血糖素参与的症状和疾病的药物。
• 2-FURANCARBOXYLIC ACID HYDRAZIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
  申请人：DAINIPPON PHARMACEUTICAL CO., LTD.

  公开号：EP1489077A1

  公开（公告）日：2004-12-22

  The present invention provides 2-furancarboxylic acid hydrazide compounds represented by General Formula (I) below, and prodrugs, physiologically acceptable salts, hydrates, solvates thereof, methods for producing them and pharmaceutical compositions containing them: wherein A is a group represented by Formula (a) or the like: (wherein either R4 or R5 represents cyano, nitro or the like, and the other represents a hydrogen atom or the like); either R1 or R2 represents a group: -D-(X)m-R6 or the like, and the other represents a group: -E-(Y)n-R7, hydrogen atom, aryl or the like; R3 is a hydrogen atom or the like; D and E independently represent aryl; X and Y independently represent 0 or the like; R6 and R7 independently represent alkyl, aryl, arylalkyl or the like; and m and n are independently 0 or 1, provided that the aryl is optionally substituted. Such compounds exhibit a potent antagonistic activity on glucagon receptor and are of use as preventive and/or therapeutic agents for symptoms and diseases in which glucagon is involved.

  本发明提供由通式表示的 2-呋喃羧酸酰肼化合物 (I)代表的2-呋喃羧酸酰肼化合物及其原药、生理上可接受的盐、水合物、溶液，以及生产它们的方法和含有它们的药物组合物： 其中 A 是由式（a）代表的基团或类似基团： (其中 R4 或 R5 代表氰基、硝基或类似物，另一个代表氢原子或类似物）； R1 或 R2 代表一个基团：-D-(X)m-R6 或类似基团，另一个代表一个基团：-E-(Y)n-R7、氢原子、芳基或类似基团； R3 是氢原子或类似物； D 和 E 各自代表芳基； X 和 Y 独立地代表 0 或类似物； R6 和 R7 独立地代表烷基、芳基、芳烷基或类似物；以及 m 和 n 独立地为 0 或 1，前提是芳基被任选取代。此类化合物对胰高血糖素受体具有强效的拮抗活性，可用作胰高血糖素相关症状和疾病的预防和/或治疗药物。
• Tobacco-specific nitrosamine detection assays and reagents
  申请人：Brown Craig Michael

  公开号：US20050043515A1

  公开（公告）日：2005-02-24

  Haptens, ligands (including antibodies), immunoassays, and test kits for detecting tobacco-specific nitrosamines (TSNAs) in samples such as tobacco products are provided. The hapten is a molecule that contains one or more structural characteristics of one or more TSNAs, and is bound to an immunogenic carrier. An antibody specific for one or more TSNAs is produced by immunizing an animal with the hapten bound to the carrier. Immunoassays and test kits using those antibodies are also provided.

  提供了用于检测烟草制品等样品中烟草特异性亚硝胺（TSNAs）的合体、配体（包括抗体）、免疫测定和检测试剂盒。合体素是一种分子，含有一种或多种 TSNA 的一种或多种结构特征，并与免疫原性载体结合。通过用与载体结合的合蛋白对动物进行免疫，可产生针对一种或多种 TSNA 的特异性抗体。此外，还提供了使用这些抗体的免疫测定和检测试剂盒。
• CELL CULTURE PLATE, DEVICES AND METHODS FOR IN VITRO EXPOSURE
  申请人：Philip Morris Products S.A.

  公开号：EP3676365A1

  公开（公告）日：2020-07-08
• IMPROVED CELL CULTURE DEVICE
  申请人：PHILIP MORRIS PRODUCTS S.A.

  公开号：US20200318048A1

  公开（公告）日：2020-10-08

  There is described a method of reducing or preventing the agglomeration of spheroids comprising the use of a cell culture device comprising: a cell culture chamber comprising a base and side walls extending from the base to enclose a volume of the cell culture chamber; an inlet in the base or side walls of the cell culture chamber adapted for fluid communication into the chamber; and an outlet in the base or side walls of the cell culture chamber adapted for fluid communication out of the chamber; wherein the base of the cell culture chamber comprises a discontinuous surface adapted to reduce or prevent the agglomeration of spheroids.